{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:41:32Z","timestamp":1771231292832,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40261-022-01218-7","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T13:03:16Z","timestamp":1667998996000},"page":"1113-1121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-2281","authenticated-orcid":false,"given":"Seth C.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Ogirala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Zeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MaryAlice","family":"Worden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth S.","family":"Koblan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"issue":"10039","key":"1218_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(15)01121-6.","journal-title":"Lancet"},{"key":"1218_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17:149\u201360. https:\/\/doi.org\/10.1002\/wps.20516.","journal-title":"World Psychiatry"},{"key":"1218_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Martin A, Patel C, Benson C, Goulding R, Kern-Sliwa J, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. NPJ Schizophr. 2022;8:5. https:\/\/doi.org\/10.1038\/s41537-021-00192-x.","journal-title":"NPJ Schizophr"},{"key":"1218_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","volume":"139","author":"M Alvarez-Jimenez","year":"2012","unstructured":"Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139:116\u201328. https:\/\/doi.org\/10.1016\/j.schres.2012.05.007.","journal-title":"Schizophr Res"},{"key":"1218_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/wps.20972","volume":"21","author":"G Ostuzzi","year":"2022","unstructured":"Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21:295\u2013307. https:\/\/doi.org\/10.1002\/wps.20972.","journal-title":"World Psychiatry"},{"key":"1218_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","volume":"160","author":"MC Ryan","year":"2003","unstructured":"Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-na\u00efve patients with schizophrenia. Am J Psychiatry. 2003;160:284\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.160.2.284.","journal-title":"Am J Psychiatry"},{"key":"1218_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/070674370605100608","volume":"51","author":"TA Cohn","year":"2006","unstructured":"Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51:382\u20136. https:\/\/doi.org\/10.1177\/070674370605100608.","journal-title":"Can J Psychiatry"},{"key":"1218_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","volume":"194","author":"E Fernandez-Egea","year":"2009","unstructured":"Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 2009;194:434\u20138. https:\/\/doi.org\/10.1192\/bjp.bp.108.052605.","journal-title":"Br J Psychiatry"},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.dsx.2017.11.006","volume":"12","author":"S Anjum","year":"2018","unstructured":"Anjum S, Bathla M, Panchal S, Singh GP, Singh M. Metabolic syndrome in drug na\u00efve schizophrenic patients. Diabetes Metab Syndr. 2018;12:135\u201340. https:\/\/doi.org\/10.1016\/j.dsx.2017.11.006.","journal-title":"Diabetes Metab Syndr"},{"key":"1218_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4088\/JCP.08m04508","volume":"70","author":"SK Verma","year":"2009","unstructured":"Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009;70:997\u20131000. https:\/\/doi.org\/10.4088\/JCP.08m04508.","journal-title":"J Clin Psychiatry"},{"key":"1218_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/schbul\/sbq058","volume":"38","author":"B Kirkpatrick","year":"2012","unstructured":"Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophr Bull. 2012;38:280\u20134. https:\/\/doi.org\/10.1093\/schbul\/sbq058.","journal-title":"Schizophr Bull"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1600-0447.2008.01158.x","volume":"117","author":"S Saddichha","year":"2008","unstructured":"Saddichha S, Manjunatha N, Ameen S, Akhtar S. Diabetes and schizophrenia: effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand. 2008;117:342\u20137. https:\/\/doi.org\/10.1111\/j.1600-0447.2008.01158.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"1218_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","volume":"2","author":"DC Henderson","year":"2015","unstructured":"Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2(5):452\u201364. https:\/\/doi.org\/10.1016\/S2215-0366(15)00115-7.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"1218_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.npp.1301209","volume":"32","author":"KL Houseknecht","year":"2007","unstructured":"Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacol. 2007;32(2):289\u201397. https:\/\/doi.org\/10.1038\/sj.npp.1301209.","journal-title":"Neuropsychopharmacol"},{"key":"1218_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","volume":"59","author":"JW Newcomer","year":"2002","unstructured":"Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment in schizophrenia. Arch Gen Psychiatry. 2002;59:337\u201345. https:\/\/doi.org\/10.1001\/archpsyc.59.4.337.","journal-title":"Arch Gen Psychiatry"},{"key":"1218_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","volume":"10","author":"TM Laursen","year":"2014","unstructured":"Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425\u201348. https:\/\/doi.org\/10.1146\/annurev-clinpsy-032813-153657.","journal-title":"Annu Rev Clin Psychol"},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382:1497\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1911772.","journal-title":"N Engl J Med"},{"key":"1218_CR18","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.3390\/ijms222413185","volume":"22","author":"N Dedic","year":"2021","unstructured":"Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22:13185. https:\/\/doi.org\/10.3390\/ijms222413185.","journal-title":"Int J Mol Sci"},{"key":"1218_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109\u201317. https:\/\/doi.org\/10.2165\/00002018-199920020-00002.","journal-title":"Drug Saf"},{"key":"1218_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200528010-00002","volume":"28","author":"C Bousquet","year":"2005","unstructured":"Bousquet C, Lagier G, Lillo-Le Lou\u00ebt A, Le Beller C, Venot A, Jaulent MC. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf. 2005;28:19\u201334. https:\/\/doi.org\/10.2165\/00002018-200528010-00002.","journal-title":"Drug Saf"},{"key":"1218_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40261-021-01094-7","volume":"41","author":"SC Hopkins","year":"2021","unstructured":"Hopkins SC, Ogirala A, Worden M, Koblan KS. Depicting safety profile of the TAAR1 agonist ulotaront relative to reactions anticipated for a dopamine D2-based pharmacological class in FAERS. Clin Drug Investig. 2021;41:1067\u201373. https:\/\/doi.org\/10.1007\/s40261-021-01094-7.","journal-title":"Clin Drug Investig"},{"key":"1218_CR22","doi-asserted-by":"publisher","DOI":"10.31478\/201906b","author":"RE Kuntz","year":"2019","unstructured":"Kuntz RE, Antman EM, Califf RM, Ingelfinger JR, Krumholz HM, Ommaya A, et al. Individual patient-level data sharing for continuous learning: a strategy for trial data sharing. NAM Perspect. 2019. https:\/\/doi.org\/10.31478\/201906b.","journal-title":"NAM Perspect"},{"key":"1218_CR23","unstructured":"A double-blind, placebo-controlled study of risperidone in children and adolescents with autistic disorder. https:\/\/yoda.yale.edu\/sites\/default\/files\/ris-usa-150_csr_synopsis.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR24","unstructured":"A randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of risperidone for the treatment of schizophrenia in adolescents. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00088075.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR25","unstructured":"The efficacy and safety of risperidone in adolescents with schizophrenia: a comparison of two dose ranges of risperidone. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00034749.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR26","unstructured":"Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer\u2019s disease. https:\/\/yoda.yale.edu\/sites\/default\/files\/ris-int-83_csr_synopsis.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR27","unstructured":"Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer\u2019s disease. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00034762.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR28","unstructured":"A randomized, double-blind, placebo-controlled study to explore the efficacy and safety of risperidone long-acting intramuscular injectable in the prevention of mood episodes in bipolar I disorder, with open-label extension. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00132678.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR29","unstructured":"A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the treatment of subjects with bipolar I disorder. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00391222.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR30","unstructured":"The efficacy and safety of flexible dose ranges of risperidone versus placebo or haloperidol in the treatment of manic episodes associated with bipolar I disorder. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00253162.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR31","unstructured":"The safety and efficacy of risperdal (risperidone) versus placebo versus haloperidol as add-on therapy to mood stabilizers in the treatment of the manic phase of bipolar disorder. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00253149.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR32","unstructured":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00249132.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR33","unstructured":"Risperidone depot (microspheres) in the treatment of subjects with schizophrenia or schizoaffective disorder: an open-label follow-up trial of RIS-INT-62 and RIS-INT-85. yoda.yale.edu\/sites\/default\/files\/nct00495118.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR34","unstructured":"CONSTATRE: Risperdal\u00ae Consta\u00ae trial of relapse prevention and effectiveness. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00216476.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR35","unstructured":"Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia after an acute episode: CSR summary not yet available. https:\/\/yoda.yale.edu\/nct00216671-early-versus-late-initiation-treatment-risperdal-consta-subjects-schizophrenia-after. Accessed 14 Oct 2022."},{"key":"1218_CR36","unstructured":"Risperidone depot (microspheres) in the treatment of subjects with schizophrenia or schizoaffective disorder: an open-label follow-up trial of RIS-INT-62 and RIS-INT-85. https:\/\/yoda.yale.edu\/sites\/default\/files\/nct00495118.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR37","unstructured":"Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. https:\/\/yoda.yale.edu\/sites\/default\/files\/ris-usa-1_csr_synopsis.pdf. Accessed 14 Oct 2022."},{"key":"1218_CR38","unstructured":"The safety and efficacy of risperidone 8 mg qd and 4 mg qd compared to placebo in the treatment of schizophrenia. yoda.yale.edu\/sites\/default\/files\/ris-usa-72_csr_synopsis.pdf. Accessed 14 Oct 2022."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01218-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01218-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01218-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T14:16:05Z","timestamp":1669731365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01218-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01218-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"19 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SCH: conceptualization, writing, and methodology; AO: methodology, formal analysis, and data curation; MAW: validation, resources, and writing; and KSK: conceptualization and writing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"This study was funded by Sunovion Pharmaceuticals Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Seth C. Hopkins, Ajay Ogirala, Courtney Zeni, Mary Alice Worden, and Kenneth S. Koblan are employees of Sunovion Pharmaceuticals Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets analyzed in the current study are available from the Yale University Open Data Access (YODA) project. The data are available upon appropriate request filed with Yale University, 25 Science Park-3rd Floor, 150 Munson St, New Haven, CT 06511, USA.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}